Success Metrics

Clinical Success Rate
76.9%

Based on 10 completed trials

Completion Rate
77%(10/13)
Active Trials
34(31%)
Results Posted
0%(0 trials)
Terminated
3(3%)

Phase Distribution

Ph phase_3
7
6%
Ph phase_1
28
25%
Ph phase_2
69
62%
Ph not_applicable
5
5%

Phase Distribution

28

Early Stage

69

Mid Stage

7

Late Stage

Phase Distribution109 total trials
Phase 1Safety & dosage
28(25.7%)
Phase 2Efficacy & side effects
69(63.3%)
Phase 3Large-scale testing
7(6.4%)
N/ANon-phased studies
5(4.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

34

trials recruiting

Total Trials

111

all time

Status Distribution
Active(44)
Completed(10)
Terminated(3)
Other(54)

Detailed Status

unknown54
Recruiting29
Completed10
Not yet recruiting8
Active, not recruiting5
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
111
Active
34
Success Rate
76.9%
Most Advanced
Phase 3

Trials by Phase

Phase 128 (25.7%)
Phase 269 (63.3%)
Phase 37 (6.4%)
N/A5 (4.6%)

Trials by Status

enrolling_by_invitation22%
unknown5449%
recruiting2926%
not_yet_recruiting87%
active_not_recruiting55%
terminated33%
completed109%

Recent Activity

Clinical Trials (111)

Showing 20 of 111 trialsScroll for more
NCT07545967Phase 1

Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy

Recruiting
NCT07518602Phase 2

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

Recruiting
NCT07507318Phase 2

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Not Yet Recruiting
NCT07493148Phase 2

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Recruiting
NCT07493109Phase 3

Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP

Recruiting
NCT07380984Phase 2

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Recruiting
NCT07320963Phase 1

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Not Yet Recruiting
NCT07415980Phase 1

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Not Yet Recruiting
NCT07397832Phase 2

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Recruiting
NCT06951997Phase 2

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Recruiting
NCT07339527Phase 1

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Not Yet Recruiting
NCT07093710Phase 1

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting
NCT07304232Phase 2

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

Recruiting
NCT05991973Phase 2

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Completed
NCT05083208Phase 1

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Terminated
NCT05566054Phase 2

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Recruiting
NCT07234162Phase 3

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Recruiting
NCT06451861Phase 2

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Recruiting
NCT05270200Phase 1

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Recruiting
NCT07159620Phase 2

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
111